Research shows use of ResMed's myAir results in better response to CPAP therapy in sleep apnoea patients

New study confirms that engaging patients with digital self-monitoring in their treatment through myAir improves adherence

ResMed today announced new European research from Price Waterhouse Coopers (PwC), revealing patients with sleep apnoea who use ResMed’s myAir have greater adherence to their CPAP therapy than patients not using myAir. myAir is ResMed’s digital and online support programme that enables patients to track their own treatment and get personalised coaching tips to support motivation.

The data, published today in a white paper, demonstrate that myAir patients use their device an average 46 minutes longer per night compared to other patients. Furthermore, the average adherence to CPAP treatment for new patients in their first week of treatment is 76% for myAir patients compared to 71% for other patients.

David Jones, Sleep Manager at University Hospital of South Manchester, United Kingdom, commented: “We know that around half of patients are not compliant with their CPAP treatment and this is a major concern for sleep treatment professionals."

The effects of poor treatment adherence are profound, not only because of the impact on patients’ quality of life, but also in terms of an increased number of accidents and emergency visits, hospitalisations and the resulting financial burden that this places on healthcare systems. These latest findings confirm that enabling patients to track and improve their CPAP device usage is an important step towards long-term compliance and better patient outcomes.”


David Jones, Sleep Manager at University Hospital of South Manchester

PwC’s “Empowering the Sleep Apnoea Patient” study analysed anonymous daily-usage data from over 23,000 patients in Germany and the United Kingdom on CPAP or automatic positive airway pressure (APAP) therapy for sleep apnoea. The patients were treated by sleep clinics and home care providers in these two countries and were all monitored via telemonitoring by their nurse or physician. Over 1,800 of these patients were also registered to ResMed’s myAir digital self-monitoring programme.

In addition to receiving data, PwC interviewed several clinics and home care providers in the United Kingdom, Germany and Finland to further investigate the positive influence of myAir on patients and clinics. Usage data and anecdotal evidence were then analysed for those patients who had and had not registered for myAir.

Christian Käfling from PwC commented: “In recent years, the introduction of telemonitoring has given sleep clinics and home care providers a tool to proactively intervene to help patients starting CPAP treatment. With myAir, telemonitoring has been taken to the next level, and this research has now confirmed that patients who use it show significantly and measurably better adherence and usage than other patients.”

Laurent Morin, ResMed’s EMEA Senior Medical Affairs director commented:

The myAir online support programme was developed based on principles of behavioural therapy. It has been well documented that patient engagement is key to successful treatment and that involving patients in their treatment improves adherence. myAir’s regular reminders, tailored coaching and positive reinforcement offer a valuable additional level of support to the care already provided by sleep clinics.”

PwC’s study findings in Europe are supported by recent research presented in the United States at CHEST 2016, the annual meeting of the American College of Chest Physicians. The data showed that patients who use a digital self-monitoring tool when treating their sleep apnoea with positive airway pressure (PAP) are significantly more likely to continue using their therapy.

The observational study of more than 128,000 U.S. patients, showed that more than 87% of PAP users were compliant on therapy when using ResMed’s myAir and AirView™, compared to 70% compliance for those using AirView alone.

Obstructive sleep apnoea is a major public health problem across Europe, and as with other illnesses, poor adherence to treatment is a significant issue for patients and the healthcare professionals who treat them.

Sleep apnoea involves the recurrent partial or complete collapse of the upper airway during sleep and is usually associated with snoring, oxygen desaturation and sleep fragmentation. CPAP devices prevent collapse of the upper airway by maintaining continuous positive air pressure throughout inspiration and expiration via a mask during sleep.

Laurent Morin commented: “While this study focused on CPAP users, we believe these results may be applied more broadly in terms of the role that online tools can have in improving medical treatment compliance overall.”

Source: ResMed


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ResMed Corp. (2017, January 12). Research shows use of ResMed's myAir results in better response to CPAP therapy in sleep apnoea patients. News-Medical. Retrieved on May 25, 2024 from

  • MLA

    ResMed Corp. "Research shows use of ResMed's myAir results in better response to CPAP therapy in sleep apnoea patients". News-Medical. 25 May 2024. <>.

  • Chicago

    ResMed Corp. "Research shows use of ResMed's myAir results in better response to CPAP therapy in sleep apnoea patients". News-Medical. (accessed May 25, 2024).

  • Harvard

    ResMed Corp. 2017. Research shows use of ResMed's myAir results in better response to CPAP therapy in sleep apnoea patients. News-Medical, viewed 25 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ResMed completes acquisition of Prague-based Unimedis